$Virax Biolabs (VRAX.US)$
Breakthrough T Cell Study: Virax Targets Long COVID and Chronic Fatigue Diagnosis Revolution

$Virax Biolabs (VRAX.US)$ Benzinga· just
Virax Biolabs Enrolls First Patients In Its UK Based Clinical Study Assessing T Cell Dysfunction In Post-acute Infection Syndromes

$Virax Biolabs (VRAX.US)$
Game-Changing Long COVID Diagnostic: Virax's New T-Cell Test Shows Promising Results

$Virax Biolabs (VRAX.US)$
Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation Meeting
Thursday, 13th March at 7:30 am
LONDON, March 13, 2025 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (NASDAQ: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced it has presented data evaluating the role of T-Cell dysfunction in pos...

$Virax Biolabs (VRAX.US)$
How Virax's Vaccine Testing Tech Could Capitalize on New Government Transparency Push

$Virax Biolabs (VRAX.US)$ see your opponents
$iSpecimen (ISPC.US)$

$Virax Biolabs (VRAX.US)$ up up

$Virax Biolabs (VRAX.US)$ hold it

$GeoVax Labs (GOVX.US)$
$iSpecimen (ISPC.US)$
$Virax Biolabs (VRAX.US)$
All plays based on recent news of FLU and COVID with ISPC being at the top due to its past runs, nano float and building social sentiment.